Research programme: secondary hyperparathyroidism therapy - LEO Pharma

Drug Profile

Research programme: secondary hyperparathyroidism therapy - LEO Pharma

Alternative Names: KH 1722; Secondary hyperparathyroidism therapy research programme - LEO Pharma

Latest Information Update: 26 Mar 2010

Price : $50

At a glance

  • Originator LEO Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperparathyroidism

Most Recent Events

  • 26 Oct 2004 Preclinical trials in Hyperparathyroidism in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top